#1 Clinical Trials Search in Europe

Mrna-3210

A groundbreaking clinical trial is underway to assess the potential of mRNA-3210 in treating phenylketonuria (PKU). This study aims to determine the safety, tolerability, and effectiveness of multiple doses of mRNA-3210 in patients with PKU. The trial involves administering the drug through intravenous infusion at varying intervals, offering hope for those affected by this genetic disorder.

Table of Contents

What is MRNA-3210?

MRNA-3210 is a new experimental medication being studied for the treatment of phenylketonuria (PKU). It is currently undergoing clinical trials to assess its safety and effectiveness in patients with this condition[1]. As an mRNA-based therapy, it represents a novel approach to treating PKU, which is a genetic disorder affecting the body’s ability to process a specific amino acid.

Target Condition: Phenylketonuria (PKU)

Phenylketonuria, often abbreviated as PKU, is a rare inherited disorder that affects the way the body processes an amino acid called phenylalanine. People with PKU cannot properly break down this amino acid, which can lead to its buildup in the body and cause serious health problems if left untreated. The condition is typically diagnosed at birth through newborn screening and requires lifelong management[1].

Clinical Trial Details

The clinical trial for MRNA-3210 is a Phase 1/2 study, which means it is one of the earliest stages of testing in humans. It is described as a “first-in-human” study, indicating that this is the first time the medication is being tested in people with PKU[1].

Study Objectives

The main goals of this clinical trial are to:

  • Assess the safety of MRNA-3210 in patients with PKU
  • Evaluate how well patients tolerate the medication
  • Study how the drug moves through and acts in the body (pharmacokinetics and pharmacodynamics)

These objectives are crucial in determining whether MRNA-3210 could potentially be a safe and effective treatment for people with PKU[1].

Treatment Administration

In this study, MRNA-3210 is administered to participants through intravenous (IV) infusion. This means the medication is delivered directly into the bloodstream through a vein. Participants will receive multiple doses of the drug, with different dosing schedules being tested:

  • Every 3 weeks (Q3W)
  • Every 2 weeks (Q2W)
  • Every week (Q1W)

The treatment course involves up to 12 doses in total. This approach allows researchers to determine the most effective and safe dosing regimen for the medication[1].

Safety Monitoring

A primary focus of the study is monitoring the safety of MRNA-3210. Researchers will be carefully tracking any side effects that occur during the treatment period and for up to 52 weeks after the last dose. These are called Treatment Emergent Adverse Events (TEAEs), which are any unfavorable medical occurrences that happen after starting the study treatment[1].

Effectiveness Measures

To determine how well MRNA-3210 works in treating PKU, the study will measure several key outcomes:

  1. Change in Blood Phenylalanine Levels: This is a crucial measure as high levels of phenylalanine in the blood are the primary concern in PKU[1].
  2. Maximum Observed Effect (Emax): This measures the greatest change in phenylalanine levels observed during the study[1].
  3. Area Under the Effect Versus Time Curve (AUEC): This provides information about the overall effect of the treatment over time[1].

These measurements will be taken from the start of treatment up to 52 weeks after the last dose, allowing researchers to assess both the immediate and long-term effects of MRNA-3210[1].

Additional Assessments

The study will also look at how MRNA-3210 behaves in the body:

  • Maximum Observed Concentration (Cmax): This measures the highest level of the drug in the blood after administration[1].
  • Area Under the Plasma Concentration-Time Curve (AUC): This provides information about the total exposure to the drug over time[1].

Additionally, researchers will monitor for the development of antibodies against polyethylene glycol, a component often used in drug formulations. This helps ensure the long-term safety and effectiveness of the treatment[1].

Aspect Details
Study Type Phase 1/2, First-in-Human, Open-Label, Dose Escalation
Condition Phenylketonuria (PKU)
Intervention mRNA-3210 via intravenous infusion
Dosing Schedule Every 3 weeks, 2 weeks, or 1 week for up to 12 doses
Primary Outcome Number of participants with Treatment Emergent Adverse Events (TEAEs)
Key Secondary Outcomes Changes in blood phenylalanine levels, drug concentration, and effect measures
Study Duration Up to 91 weeks (including 52 weeks post-treatment follow-up)

FAQ

  • What is the main goal of this clinical trial? The main goal of this study is to assess the safety and tolerability of multiple doses of mRNA-3210 in participants with phenylketonuria (PKU).
  • How is mRNA-3210 administered to participants? mRNA-3210 is administered to participants through intravenous (IV) infusion. Participants receive a single dose every 3 weeks, every 2 weeks, or every week for up to 12 doses.
  • What are the primary outcomes being measured in this trial? The primary outcome being measured is the number of participants experiencing Treatment Emergent Adverse Events (TEAEs) over a period of up to 91 weeks.
  • What are some of the secondary outcomes being evaluated? Secondary outcomes include changes in blood phenylalanine levels, maximum observed effect, area under the effect versus time curve, maximum observed concentration of the drug, and the presence of anti-polyethylene glycol antibodies.
  • How long does the trial last for each participant? The trial lasts up to 91 weeks for each participant, which includes the treatment period and a follow-up period of 52 weeks after the end of treatment.

Ongoing Clinical Trials on Mrna-3210

  • Study to Evaluate mRNA-3210 for Safety and Tolerability in Patients with Phenylketonuria

    Not recruiting

    1 1 1
    Investigated drugs:
    France Italy Spain

Glossary

  • Phenylketonuria (PKU): A genetic disorder that affects the body's ability to break down the amino acid phenylalanine, leading to its buildup in the body.
  • mRNA-3210: The experimental drug being tested in this clinical trial for the treatment of phenylketonuria.
  • Intravenous (IV) infusion: A method of delivering medication directly into a vein using a needle or catheter.
  • Treatment Emergent Adverse Events (TEAEs): Any unfavorable medical occurrence that appears or worsens after the start of treatment in a clinical study.
  • Phenylalanine: An essential amino acid that people with PKU have difficulty metabolizing, leading to its accumulation in the body.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics: The study of how a drug affects the body, including its mechanism of action and relationship between drug concentration and effect.
  • Maximum Observed Effect (Emax): The greatest effect observed from a drug, used to measure its efficacy.
  • Area Under the Effect Versus Time Curve (AUEC): A measure of the total effect of a drug over time.
  • Maximum Observed Concentration (Cmax): The highest concentration of a drug observed in the blood after administration.
  • Area Under the Plasma Concentration-Time Curve (AUC): A measure of the total exposure to a drug over time.
  • Anti-Polyethylene Glycol Antibodies: Antibodies that the body may produce in response to polyethylene glycol, a compound sometimes used in drug formulations.

References